IP Library Granted Patent US 9,604,028
Granted Patent B2
US 9,604,028 · App. 14/612,266 · Granted Mar 28, 2017

Systems and devices for generating nitric oxide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,604,028
App. No.
14/612,266
Granted
Mar 28, 2017
Kind
B2
Abstract

Various systems and devices for generating nitric oxide are disclosed herein. According to one embodiment, the device includes a body having an inlet, an outlet, and a porous solid matrix positioned with the body. The porous solid matrix is coated with an aqueous solution of an antioxidant, wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the solid matrix to convert nitrogen dioxide in the gas flow into nitric oxide. The porous solid matrix allows the device to be used in any orientation. Additionally, the porous solid matrix provides a rigid structure suitable to withstand vibrations and abuse without compromising device functionality.

Claims (15)

1. A method of delivering nitric oxide to a patient, comprising:

providing a system including:

a gas source of nitrogen dioxide, dinitrogen tetroxide, or nitric oxide;

a first device having a receptacle including an inlet, an outlet and a diverter, a porous solid matrix including an antioxidant positioned within the receptacle, and a space between the receptacle and the porous solid matrix, wherein the space has a width, which is the distance between an outer surface of the porous solid matrix to the receptacle, and the width of the space is variable along a length of the receptacle, and wherein the inlet is configured to receive a gas flow, the diverter directs the gas flow to the space between the receptacle and the porous solid matrix, and the gas flow is fluidly communicated to the outlet through the porous solid matrix to convert nitrogen dioxide in the gas flow into nitric oxide; and

a patient interface coupled to the outlet of the first device, and delivering nitric oxide to the patient through the patient interface.

2. The method system of claim 1 , wherein the system further includes a humidifier positioned between the gas source and the first device.

3. The method of claim 2 , wherein the humidifier is integral with the first device.

4. The method of claim 2 , wherein the humidifier has a temperature between 18° C. and 23° C.

5. The method of claim 2 , wherein the system further comprises:

a second humidifier positioned after the first device; and

a second device positioned after the second humidifier, the second device having a receptacle including an inlet, an outlet and a diverter, a porous solid matrix including an antioxidant positioned within the receptacle, and a space between the receptacle and the porous solid matrix, wherein the space has a width, which is the distance between an outer surface of the porous solid matrix to the receptacle, and the width of the space is variable along a length of the receptacle, and wherein the inlet is configured to receive a gas flow, the diverter directs the gas flow to the space between the receptacle and the porous solid matrix, and the gas flow is fluidly communicated to the outlet through the porous solid matrix to convert nitrogen dioxide in the gas flow into nitric oxide.

6. The method of claim 1 , further comprising a humidifier positioned prior to the patient interface.

7. The method of claim 6 , wherein the humidifier has a temperature of between 32° C. and 37° C.

8. The method of claim 1 , wherein the patient is diagnosed with one or more of acute pulmonary vasoconstriction, traumatic injury, aspiration or inhalation injury, fat embolism in the lung, acidosis, inflammation of the lung, adult respiratory distress syndrome, acute pulmonary edema, acute mountain sickness, post cardiac surgery acute pulmonary hypertension, persistent pulmonary hypertension of a newborn, perinatal aspiration syndrome, haline membrane disease, acute pulmonary thromboembolism, heparin-protamine reactions, sepsis, asthma, status asthmaticus, hypoxia, chronic pulmonary hypertension, bronchopulmonary dysplasia, chronic pulmonary thromboembolism, idiopathic pulmonary hypertension, primary pulmonary hypertension, or chronic hypoxia.

9. The method of claim 1 , wherein the patient is treated with nitric oxide at a concentration of greater than 10, 40, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 ppm.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: VERO BIOTECH INC.
Reel/Frame 075308/0198 →
SECURITY INTEREST Recorded Mar 16, 2026
From: VERO BIOTECH INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS COLLATERAL AGENT
Reel/Frame 075117/0935 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 3, 2024
From: RUNWAY GROWTH FINANCE CORP (F/K/A RUNWAY GROWTH CREDIT FUND INC.)
To: VERO BIOTECH INC. (F/K/A VERO BIOTECH LLC)
Reel/Frame 066186/0611 →
SECURITY INTEREST Recorded Jan 3, 2024
From: VERO BIOTECH INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066187/0865 →
CHANGE OF NAME Recorded Feb 14, 2022
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 059085/0418 →
SECURITY INTEREST Recorded Dec 29, 2020
From: VERO BIOTECH LLC
To: RUNWAY GROWTH CREDIT FUND INC.
Reel/Frame 054866/0589 →
CHANGE OF NAME Recorded Jun 6, 2018
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 046304/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2015
From: FINE, DAVID H.; JOHNSON, BRYAN; VASQUEZ, GREGORY
To: GENO LLC
Reel/Frame 035637/0781 →